Guangxi Liuzhou Pharm Co Ltd
Guangxi LiuYao Group Co., Ltd engages in the wholesale and retail of pharmaceutical products in China. It offers various types of medicines, medical devices, consumables, and test reagents through online pharmacies and terminal physical pharmacies. The company was founded in 1981 and is based in Liuzhou, China.
Guangxi Liuzhou Pharm Co Ltd (603368) - Net Assets
Latest net assets as of September 2025: CN¥8.14 Billion CNY
Based on the latest financial reports, Guangxi Liuzhou Pharm Co Ltd (603368) has net assets worth CN¥8.14 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥21.18 Billion) and total liabilities (CN¥13.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.14 Billion |
| % of Total Assets | 38.41% |
| Annual Growth Rate | 29.54% |
| 5-Year Change | 45.78% |
| 10-Year Change | 483.32% |
| Growth Volatility | 44.02 |
Guangxi Liuzhou Pharm Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Guangxi Liuzhou Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guangxi Liuzhou Pharm Co Ltd (2011–2024)
The table below shows the annual net assets of Guangxi Liuzhou Pharm Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.94 Billion | +12.36% |
| 2023-12-31 | CN¥7.06 Billion | +10.97% |
| 2022-12-31 | CN¥6.37 Billion | +9.63% |
| 2021-12-31 | CN¥5.81 Billion | +6.64% |
| 2020-12-31 | CN¥5.44 Billion | +16.90% |
| 2019-12-31 | CN¥4.66 Billion | +15.08% |
| 2018-12-31 | CN¥4.05 Billion | +13.41% |
| 2017-12-31 | CN¥3.57 Billion | +10.22% |
| 2016-12-31 | CN¥3.24 Billion | +137.96% |
| 2015-12-31 | CN¥1.36 Billion | +15.91% |
| 2014-12-31 | CN¥1.17 Billion | +134.31% |
| 2013-12-31 | CN¥501.00 Million | +32.34% |
| 2012-12-31 | CN¥378.59 Million | +38.05% |
| 2011-12-31 | CN¥274.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guangxi Liuzhou Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4873.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.52 Billion | 59.27% |
| Common Stock | CN¥399.03 Million | 5.23% |
| Other Comprehensive Income | CN¥421.66 Million | 5.53% |
| Other Components | CN¥2.28 Billion | 29.96% |
| Total Equity | CN¥7.62 Billion | 100.00% |
Guangxi Liuzhou Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Guangxi Liuzhou Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Transcat Inc
NASDAQ:TRNS
|
$667.36 Million |
|
DINE S.A.B. de C.V
MX:DINEB
|
$667.42 Million |
|
Guangzhou Wondfo Biotech Co Ltd
SHE:300482
|
$667.47 Million |
|
Investors Real Estate Trust
F:WXC1
|
$667.49 Million |
|
VALNEVA SE SP.ADS/2
F:AYJ0
|
$667.13 Million |
|
Cofoe Medical Technology Co.Ltd.
SHE:301087
|
$666.89 Million |
|
Motorcomm Electronic Technology Co. Ltd. A
SHG:688515
|
$666.84 Million |
|
Kissei Pharmaceutical Co. Ltd
PINK:KSPHF
|
$666.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangxi Liuzhou Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,617,614,662 to 7,624,408,552, a change of 1,006,793,890 (15.2%).
- Net income of 854,872,389 contributed positively to equity growth.
- Dividend payments of 412,350,265 reduced retained earnings.
- Share repurchases of 2,148,258 reduced equity.
- Other comprehensive income decreased equity by 190.
- Other factors increased equity by 566,420,214.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥854.87 Million | +11.21% |
| Dividends Paid | CN¥412.35 Million | -5.41% |
| Share Repurchases | CN¥2.15 Million | -0.03% |
| Other Comprehensive Income | CN¥-190.00 | -0.0% |
| Other Changes | CN¥566.42 Million | +7.43% |
| Total Change | CN¥- | 15.21% |
Book Value vs Market Value Analysis
This analysis compares Guangxi Liuzhou Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 14.61x to 0.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.20 | CN¥17.51 | x |
| 2012-12-31 | CN¥1.65 | CN¥17.51 | x |
| 2013-12-31 | CN¥2.18 | CN¥17.51 | x |
| 2014-12-31 | CN¥4.94 | CN¥17.51 | x |
| 2015-12-31 | CN¥4.63 | CN¥17.51 | x |
| 2016-12-31 | CN¥11.86 | CN¥17.51 | x |
| 2017-12-31 | CN¥9.63 | CN¥17.51 | x |
| 2018-12-31 | CN¥10.61 | CN¥17.51 | x |
| 2019-12-31 | CN¥12.06 | CN¥17.51 | x |
| 2020-12-31 | CN¥14.09 | CN¥17.51 | x |
| 2021-12-31 | CN¥15.09 | CN¥17.51 | x |
| 2022-12-31 | CN¥16.51 | CN¥17.51 | x |
| 2023-12-31 | CN¥18.30 | CN¥17.51 | x |
| 2024-12-31 | CN¥19.71 | CN¥17.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangxi Liuzhou Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.21%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.04%
- • Asset Turnover: 1.00x
- • Equity Multiplier: 2.79x
- Recent ROE (11.21%) is below the historical average (16.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 30.46% | 3.06% | 1.73x | 5.74x | CN¥56.11 Million |
| 2012 | 27.56% | 2.93% | 1.75x | 5.36x | CN¥66.50 Million |
| 2013 | 29.82% | 3.29% | 1.69x | 5.38x | CN¥99.32 Million |
| 2014 | 14.69% | 3.00% | 1.51x | 3.23x | CN¥54.23 Million |
| 2015 | 15.68% | 3.20% | 1.51x | 3.24x | CN¥75.46 Million |
| 2016 | 10.06% | 4.25% | 1.20x | 1.97x | CN¥2.01 Million |
| 2017 | 11.50% | 4.25% | 1.25x | 2.16x | CN¥52.20 Million |
| 2018 | 13.73% | 4.51% | 1.20x | 2.54x | CN¥143.54 Million |
| 2019 | 15.67% | 4.61% | 1.24x | 2.73x | CN¥248.15 Million |
| 2020 | 13.96% | 4.54% | 1.06x | 2.90x | CN¥201.85 Million |
| 2021 | 10.33% | 3.29% | 1.08x | 2.91x | CN¥17.81 Million |
| 2022 | 11.75% | 3.68% | 1.02x | 3.12x | CN¥104.62 Million |
| 2023 | 12.84% | 4.08% | 1.03x | 3.05x | CN¥187.83 Million |
| 2024 | 11.21% | 4.04% | 1.00x | 2.79x | CN¥92.43 Million |
Industry Comparison
This section compares Guangxi Liuzhou Pharm Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $5,102,531,246
- Average return on equity (ROE) among peers: 3.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangxi Liuzhou Pharm Co Ltd (603368) | CN¥8.14 Billion | 30.46% | 1.60x | $667.23 Million |
| C.Q. Pharmaceutical Holding Co Ltd (000950) | $329.08 Million | -29.91% | 1.75x | $539.38 Million |
| Shenzhen Glory Medical Co Ltd (002551) | $2.82 Billion | 2.12% | 0.68x | $266.49 Million |
| Shandong Realcan Pharmaceutical Co Ltd (002589) | $5.69 Billion | 0.36% | 1.81x | $435.98 Million |
| Qingdao Baheal Medical INC. (301015) | $1.50 Billion | 18.20% | 1.70x | $456.67 Million |
| China Meheco Co Ltd (600056) | $382.07 Million | 11.69% | 1.02x | $1.02 Billion |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) | $3.90 Billion | 7.38% | 0.25x | $3.04 Billion |
| Liaoning Cheng Da Co Ltd (600739) | $21.37 Billion | 6.77% | 0.66x | $1.40 Billion |
| Jointown Pharmaceutical Group Co Ltd (600998) | $4.84 Billion | 8.53% | 2.06x | $1.61 Billion |